The anti-cancer drug is based on SoAP technology, which belongs to the phage display group of technologies.
But cancer experts say it sounds too good to be true, particularly in light of International Agency for Research on Cancer reports showing an estimated 18.1 million new cancer cases are diagnosed worldwide each year.
The idea is similar to that of a Nobel Prize victor in which scientists worked on phage display in the directed evolution of new proteins in particular, to produce antibody therapeutics.
A team of researchers in Israel told The Jerusalem Post Monday that they had created an antidote for cancer - a drug called MuTaTo, meaning multiobjective toxin - that will work immediately and take mere weeks to destroy all cancerous cells in the body.
Using the similar science to last year's chemistry win at Nobel, AEBi has been able to create a multi-target toxin - which they're calling MuTaTo - that'll be a completely customizable anti-cancer drug.
"The probability of having multiple mutations that would modify all targeted receptors simultaneously decreases dramatically with the number of targets used", he continued.
Mutations in the targets - or downstream in their physiological pathways - could make the targets not relevant to the cancer nature of the cell, and hence the drug attacking it is rendered ineffective...
"Instead of attacking receptors one at a time, we attack receptors three at a time - not even cancer can mutate three receptors at the same time", Morad added. The experiment showed inhibited human cancer cell growth and had no effect on healthy mice cells, according to the paper. With the correct biopsy, specialized physicians can design a customized "cocktail" for each type of cancer.
The difference between MuTaTo and traditional cancer treatments now in play is pretty drastic.
The innovators started off by looking at why other cancer-fighting treatments had failed in the past, which company CEP Dr Ilan Morad explained was because most cancer drugs attack a specific target on, or in the cancer cell.
Aridor said the company's first target is lung cancer and that it's working on others.